{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:35:58Z","timestamp":1760240158684,"version":"build-2065373602"},"reference-count":91,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/DTP-FTO\/1489\/2014\u2014POCI-01-0145-FEDER-016537"],"award-info":[{"award-number":["PTDC\/DTP-FTO\/1489\/2014\u2014POCI-01-0145-FEDER-016537"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms are still unclear. In the present study, the role of the main metabolites regarding FAC-induced cardiotoxicity was assessed at clinical relevant concentrations. Seven-day differentiated H9c2 cells were exposed for 48 h to the main metabolites of FAC, namely the metabolite of 5-FU, \u03b1-fluoro-\u03b2-alanine (FBAL, 50 or 100 \u03bcM), of DOX, doxorubicinol (DOXOL, 0.2 or 1 \u03bcM), and of CYA, acrolein (ACRO, 1 or 10 \u03bcM), as well as to their combination. The parent drugs (5-FU 50 \u03bcM, DOX 1 \u03bcM, and CYA 50 \u03bcM) were also tested isolated or in combination with the metabolites. Putative cytotoxicity was evaluated through phase contrast microscopy, Hoechst staining, membrane mitochondrial potential, and by two cytotoxicity assays: the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the neutral red (NR) lysosomal incorporation. The metabolite DOXOL was more toxic than FBAL and ACRO in the MTT and NR assays. When in combination, neither FBAL nor ACRO increased DOXOL-induced cytotoxicity. No nuclear condensation was observed for any of the tested combinations; however, a significant mitochondrial potential depolarization after FBAL 100 \u03bcM + DOXOL 1 \u03bcM + ACRO 10 \u03bcM or FBAL 100 \u03bcM + DOXOL 1 \u03bcM exposure was seen at 48 h. When tested alone DOX 1 \u03bcM was more cytotoxic than all the parent drugs and metabolites in both the cytotoxicity assays performed. These results demonstrated that DOXOL was the most toxic of all the metabolites tested; nonetheless, the metabolites do not seem to be the major contributors to FAC-induced cardiotoxicity in this cardiac model.<\/jats:p>","DOI":"10.3390\/biom9030098","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T03:49:31Z","timestamp":1552362571000},"page":"98","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2775-3147","authenticated-orcid":false,"given":"Ana","family":"Reis-Mendes","sequence":"first","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-3494","authenticated-orcid":false,"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-5119","authenticated-orcid":false,"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"CIIMAR\u2013Interdisciplinary Centre of Marine and Environmental Research, 4450-208 Porto, Portugal"}]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-2756","authenticated-orcid":false,"given":"Vera Marisa","family":"Costa","sequence":"additional","affiliation":[{"name":"UCIBIO, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2014.58.2320","article-title":"Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011","volume":"33","author":"Shih","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Anampa, J., Makower, D., and Sparano, J.A. (2015). Progress in adjuvant chemotherapy for breast cancer: An overview. BMC Med., 13.","DOI":"10.1186\/s12916-015-0439-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1081\/CNV-120025086","article-title":"A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer","volume":"21","author":"Chao","year":"2003","journal-title":"Cancer Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40261-018-0655-z","article-title":"Efficacy and safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally\/regionally advanced, HER2-negative, grade III at premenopausal status breast cancer: A phase II study","volume":"38","author":"Tampaki","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Veronese, P., Hachul, D.T., Scanavacca, M.I., Hajjar, L.A., Wu, T.C., Sacilotto, L., Veronese, C., and Darrieux, F. (2018). Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196763"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/annonc\/mdg260","article-title":"Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group","volume":"14","author":"Martin","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Liutkauskiene, S., Grizas, S., Jureniene, K., Suipyte, J., Statnickaite, A., and Juozaityte, E. (2018). Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4365-y"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/03602532.2017.1316285","article-title":"The importance of drug metabolites synthesis: The case-study of cardiotoxic anticancer drugs","volume":"49","author":"Hrynchak","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1389200216666151103114926","article-title":"The role of the metabolism of anticancer drugs in their induced-cardiotoxicity","volume":"17","author":"Sousa","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/tx400130v","article-title":"The heart as a target for xenobiotic toxicity: The cardiac susceptibility to oxidative stress","volume":"26","author":"Costa","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","article-title":"5-Fluorouracil induced cardiotoxicity: Review of the literature","volume":"19","author":"Sorrentino","year":"2012","journal-title":"Cardiol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: Focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_14","first-page":"OE01","article-title":"Acute cyclophosphamide hemorrhagic myopericarditis: Dilemma case report, literature review and proposed diagnostic criteria","volume":"9","author":"Wadia","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5694\/j.1326-5377.1980.tb134771.x","article-title":"Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma","volume":"1","author":"Dalley","year":"1980","journal-title":"Med. J. Aust."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1200\/JCO.2005.06.236","article-title":"Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer centre","volume":"23","author":"Bontenbal","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2012.46.9841","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM\/2003-02 study","volume":"31","author":"Martin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","first-page":"260","article-title":"Effect of aloe vera (Aloe barbadensis Miller) gel on doxorubicin-induced myocardial oxidative stress and calcium overload in albino rats","volume":"49","author":"Kaithwas","year":"2011","journal-title":"Indian J. Exp. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4048\/jbc.2012.15.3.306","article-title":"Impact of breast cancer and combination chemotherapy on oxidative stress, hepatic and cardiac markers","volume":"15","author":"Amin","year":"2012","journal-title":"J. Breast Cancer"},{"key":"ref_20","first-page":"41","article-title":"Cardioprotective effect of lipistat against doxorubicin induced myocardial toxicity in albino rats","volume":"47","author":"Koti","year":"2009","journal-title":"Indian J. Exp. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000227467","article-title":"A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide","volume":"52","author":"Kolaric","year":"1995","journal-title":"Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00000421-198904000-00007","article-title":"Ten-year results of FAC adjuvant chemotherapy trial in breast cancer","volume":"12","author":"Buzdar","year":"1989","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_23","first-page":"17","article-title":"Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III","volume":"22","author":"Bustova","year":"2009","journal-title":"Klin. Onkol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-Year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-9966-31-60","article-title":"5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress","volume":"31","author":"Lamberti","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/009841000156709","article-title":"Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil","volume":"59","author":"Durak","year":"2000","journal-title":"J. Toxicol. Environ. Health A"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4161\/cbt.7.7.6207","article-title":"Serum levels of NF\u03baB and pro-inflammatory cytokines following administration of mucotoxic drugs","volume":"7","author":"Logan","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_28","first-page":"2481","article-title":"Cytokine changes in response to radio-\/chemotherapeutic treatment in head and neck cancer","volume":"33","author":"Reers","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E1440","DOI":"10.1152\/ajpendo.00587.2011","article-title":"Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss","volume":"302","author":"Abimosleh","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review","volume":"7","author":"Martino","year":"2002","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-FU metabolism in cancer and orally-administrable 5-FU drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.acr.2014.10.007","article-title":"Role of ABC transporters in fluoropyrimidine-based chemotherapy response","volume":"125","author":"Nies","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00280-014-2541-6","article-title":"Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil","volume":"74","author":"Jamieson","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10147-005-0516-7","article-title":"5-Fluorouracil cardiotoxicity induced by \u03b1-fluoro-\u03b2-alanine","volume":"10","author":"Muneoka","year":"2005","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_35","first-page":"1680","article-title":"Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment","volume":"48","author":"Hull","year":"1988","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.bjc.6601224","article-title":"Plasma concentrations of 5-fluorouracil and F-\u03b2-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil","volume":"89","author":"Yamada","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00280-004-0900-4","article-title":"Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma","volume":"55","author":"Joerger","year":"2005","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200746120-00005","article-title":"Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG","volume":"46","author":"Joerger","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_39","first-page":"133","article-title":"Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein","volume":"27","author":"Ren","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"ref_40","first-page":"79","article-title":"Adriamycin metabolism in man. Evidence from urinary metabolites","volume":"4","author":"Takanashi","year":"1976","journal-title":"Drug Metab. Dispos."},{"key":"ref_41","first-page":"1945","article-title":"Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues","volume":"13","author":"Stewart","year":"1993","journal-title":"Anticancer Res."},{"key":"ref_42","first-page":"415","article-title":"[Systemic chemotherapy of mammary carcinoma: Plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer","volume":"11","author":"Murayama","year":"1984","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00003088-200241060-00004","article-title":"Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs","volume":"41","author":"Danesi","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-80-2-249","article-title":"Adriamycin. A new anticancer drug with significant clinical activity","volume":"80","author":"Blum","year":"1974","journal-title":"Ann. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(88)90004-6","article-title":"Metabolism of oxazaphosphorines","volume":"37","author":"Sladek","year":"1988","journal-title":"Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"Huitema","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00228-011-1134-0","article-title":"Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients","volume":"68","author":"Afsar","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0009-2797(94)90091-4","article-title":"Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro","volume":"93","author":"Dorr","year":"1994","journal-title":"Chem. Biol. Interact."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kurauchi, K., Nishikawa, T., Miyahara, E., Okamoto, Y., and Kawano, Y. (2017). Role of metabolites of cyclophosphamide in cardiotoxicity. BMC Res. Notes, 10.","DOI":"10.1186\/s13104-017-2726-2"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/jm00157a015","article-title":"31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites","volume":"29","author":"Boyd","year":"1986","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12013-011-9169-5","article-title":"Acrolein, an environmental toxin, induces cardiomyocyte apoptosis via elevated intracellular calcium and free radicals","volume":"61","author":"Wang","year":"2011","journal-title":"Cell Biochem. Biophys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"H2050","DOI":"10.1152\/ajpheart.00120.2011","article-title":"Chronic oral exposure to the aldehyde pollutant acrolein induces dilated cardiomyopathy","volume":"301","author":"Ismahil","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.apsb.2012.02.004","article-title":"Oxazaphosphorine bioactivation and detoxification the role of xenobiotic receptors","volume":"2","author":"Wang","year":"2012","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Pereira-Oliveira, M., Reis-Mendes, A., Carvalho, F., Remiao, F., Pinto, M., Bastos, M.L., and Costa, V.M. (2019). Doxorubicin is key for the cardiotoxicity of fac (5-fluorouracil + adriamycin + cyclophosphamide) combination in H9c2 differentiated cells. Biomolecules, 9.","DOI":"10.3390\/biom9010021"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nishikawa, T., Miyahara, E., Kurauchi, K., Watanabe, E., Ikawa, K., Asaba, K., Tanabe, T., Okamoto, Y., and Kawano, Y. (2015). Mechanisms of fatal cardiotoxicity following high-dose cyclophosphamide therapy and a method for its prevention. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131394"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-4827(76)90447-X","article-title":"Properties of a clonal muscle cell line from rat heart","volume":"98","author":"Kimes","year":"1976","journal-title":"Exp. Cell Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Ruiz, M., Courilleau, D., Jullian, J.C., Fortin, D., Ventura-Clapier, R., Blondeau, J.P., and Garnier, A. (2012). A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1\u03b1 expression and mitochondrial biogenesis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046753"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00204-016-1839-z","article-title":"Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy","volume":"91","author":"Gomes","year":"2017","journal-title":"Arch. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"29063","DOI":"10.1074\/jbc.274.41.29063","article-title":"Modulation of l-type calcium channel expression during retinoic acid-induced differentiation of H9c2 cardiac cells","volume":"274","author":"Menard","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12012-011-9112-4","article-title":"Metabolic remodeling during H9c2 myoblast differentiation: Relevance for in vitro toxicity studies","volume":"11","author":"Pereira","year":"2011","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12012-012-9177-8","article-title":"Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts","volume":"12","author":"Branco","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00280-009-0932-x","article-title":"Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts","volume":"64","author":"Sardao","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10565-008-9070-1","article-title":"Morphological alterations induced by doxorubicin on H9c2 myoblasts: Nuclear, mitochondrial, and cytoskeletal targets","volume":"25","author":"Sardao","year":"2009","journal-title":"Cell Biol. Toxicol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Branco, A.F., Pereira, S.P., Gonzalez, S., Gusev, O., Rizvanov, A.A., and Oliveira, P.J. (2015). Gene expression profiling of H9c2 myoblast differentiation towards a cardiac-like phenotype. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129303"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Almeida, D., Pinho, R., Correia, V., Soares, J., Bastos, M.L., Carvalho, F., Capela, J.P., and Costa, V.M. (2018). Mitoxantrone is more toxic than doxorubicin in SH-SY5Y human cells: A \u2018chemobrain\u2019 in vitro study. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020041"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1021\/bi00232a015","article-title":"J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential","volume":"30","author":"Reers","year":"1991","journal-title":"Biochemistry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1006\/bbrc.1993.2438","article-title":"A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5\u2032,6,6\u2032-tetrachloro-1,1\u2032,3,3\u2032-tetraethylbenzimidazolcarbocyanine iodide (JC-1)","volume":"197","author":"Cossarizza","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"bcr-2016-219162","DOI":"10.1136\/bcr-2016-219162","article-title":"Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer","volume":"2017","author":"Franck","year":"2017","journal-title":"BMJ Case Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0021-5198(19)52945-6","article-title":"Cardiotoxic effects of 5-fluorouracil in the guinea pig","volume":"30","author":"Matsubara","year":"1980","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/00001813-200411000-00006","article-title":"Lack of contribution of dihydrofluorouracil and \u03b1-fluoro-\u03b2-alanine to the cytotoxicity of 5\u2032-deoxy-5-fluorouridine on human keratinocytes","volume":"15","author":"Fischel","year":"2004","journal-title":"Anticancer Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/jpet.113.206805","article-title":"A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin","volume":"347","author":"Bains","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/tx000013q","article-title":"Doxorubicin metabolism and toxicity in human myocardium: Role of cytoplasmic deglycosidation and carbonyl reduction","volume":"13","author":"Licata","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI117833","article-title":"Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity","volume":"95","author":"Minotti","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1096\/fasebj.12.7.541","article-title":"The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase\/iron regulatory protein-1 in cytosolic fractions from human myocardium","volume":"12","author":"Minotti","year":"1998","journal-title":"FASEB J."},{"key":"ref_77","first-page":"6602","article-title":"Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1","volume":"63","author":"Olson","year":"2003","journal-title":"Cancer Res."},{"key":"ref_78","first-page":"5158","article-title":"Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice","volume":"60","author":"Forrest","year":"2000","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1096\/fasebj.13.2.199","article-title":"Role of iron in anthracycline cardiotoxicity: New tunes for an old song?","volume":"13","author":"Minotti","year":"1999","journal-title":"FASEB J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: Process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1111\/bph.12995","article-title":"Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: A correlation with the inhibition of carbonyl reductase-mediated metabolism","volume":"172","author":"Zhou","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.toxlet.2014.06.021","article-title":"Acrolein induced both pulmonary inflammation and the death of lung epithelial cells","volume":"229","author":"Sun","year":"2014","journal-title":"Toxicol. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1074\/jbc.274.14.9200","article-title":"Acrolein causes inhibitor \u03baB-independent decreases in nuclear factor \u03baB activation in human lung adenocarcinoma (A549) cells","volume":"274","author":"Horton","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/tx015552p","article-title":"Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications","volume":"15","author":"Biswal","year":"2002","journal-title":"Chem. Res. Toxicol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1021\/tx900147g","article-title":"Molecular mechanisms of 4-hydroxy-2-nonenal and acrolein toxicity: Nucleophilic targets and adduct formation","volume":"22","author":"LoPachin","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","article-title":"Pathways of cardiac toxicity: Comparison between chemotherapeutic drugs doxorubicin and mitoxantrone","volume":"90","author":"Damiani","year":"2016","journal-title":"Arch. Toxicol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev.pharmtox.46.120604.141122","article-title":"Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling","volume":"46","author":"Hansen","year":"2006","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_88","first-page":"1231","article-title":"Superoxide anion production by adriamycinol from cardiac sarcosomes and by mitochondrial nadh dehydrogenase","volume":"6","author":"Gervasi","year":"1986","journal-title":"Anticancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","article-title":"The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions","volume":"262","author":"Boucek","year":"1987","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.12659\/MSM.910537","article-title":"Mitochondrial dynamics in rat heart induced by 5-fluorouracil","volume":"24","author":"Zhang","year":"2018","journal-title":"Med. Sci. Monit."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/3\/98\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:37:59Z","timestamp":1760186279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/9\/3\/98"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["biom9030098"],"URL":"https:\/\/doi.org\/10.3390\/biom9030098","relation":{},"ISSN":["2218-273X"],"issn-type":[{"type":"electronic","value":"2218-273X"}],"subject":[],"published":{"date-parts":[[2019,3,11]]}}}